{"id":"W2899230583","doi":"10.1136/annrheumdis-2018-eular.2137","title":"THU0333 Efficacy and safety of ixekizumab in patients with active psoriatic arthritis: three year results from a phase 3 study (SPIRIT-P1)","year":2018,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"Krembil Foundation","funders":"NordForsk; Oak Foundation","keywords":"Medicine; Ixekizumab; Discontinuation; Psoriatic arthritis; Internal medicine; Adverse effect; Placebo; Rheumatology; Psoriasis; Physical therapy; Arthritis; Secukinumab; Dermatology; Alternative medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002181518,0.0008984841,0.002166768,0.0002705465,0.0004201811,0.001047215,0.0006652381,0.001065289,0.002056445],"category_scores_gemma":[0.0008225012,0.0003795913,0.002337242,0.0003486373,0.0007005916,0.0007586411,0.0003443821,0.003270527,0.0006039931],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006666353,"about_ca_system_score_gemma":0.001014002,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001179375,"about_ca_topic_score_gemma":0.001869909,"domain_scores_codex":[0.9993445,0.0002880656,0.00003575656,0.00008644522,0.00007900565,0.0001662602],"domain_scores_gemma":[0.9992754,0.000166725,0.0001537716,0.00008233912,0.00004784088,0.0002738621],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7078582,0.03816384,0.01664243,0.000858099,0.003498866,0.0003969344,0.000434038,0.0035011,0.0492575,0.0002508084,0.004679232,0.174459],"study_design_scores_gemma":[0.4139711,0.4934337,0.08066445,0.0000652396,0.001852948,0.0005476152,0.0001569587,0.001823668,0.004765909,0.0002792032,0.002368561,0.00007054648],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9954074,0.002180691,0.0003511075,0.000265813,0.00004959678,0.0003187606,0.0006127391,0.0000746867,0.0007391057],"genre_scores_gemma":[0.9953372,0.0009221376,0.0007274632,0.0004942291,0.00009086221,0.0002988876,0.001241441,0.0000259461,0.0008616508],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002181518,"threshold_uncertainty_score":0.01153708,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0212153636489128,"score_gpt":0.2711073827062123,"score_spread":0.2498920190572995,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}